Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We from different sides of the track
Where I'm from I was taught how to shoot craps - just facts
It comes in handy when rolling the dice on crap exchanges (CSE/OTC)
A stock block and the block is always hot
I know the odds and I know my opps
Yameen
Money $ h o t
Outro
Here's where Algernon and Smackie Mackie are in lockstep
The following is an excerpt from the SHORT FORM BASE SHELF PROSPECTUS dated May 5, 2021
webfiles.thecse.com/AGN_-_Final_Short_Form_Base_Shelf_Prospectus_dd_May_5_2021.pdf?BXNf.kOYWuNyX76yg4nPIsRYETVIANj3=
Uncle buckshot, I see the link posted at CEO.CA by PennyQueen. The link is to Research Capital (SMACKIE MACKIE) latest coverage of Algernon Pharmaceuticals Inc. They placed a 25 $ Speculative Buy rating on the company which equates to 25 Cent CAD pre consolidation of shares.
TWENTY FIVE CENT CAD = TWENTY CENT USD
A FRIGGING PRE SPLIT 20 CENT BUY RATING
Once again, SMACKIE MACKIE has low-ball numbers for a potential low-ball toxic financing by SMACKIE MACKIE.
Let it be known, if management stumbles it's way back down the TOXIC FINANCING road of fire sale shares plus warrants they will have once again lost my support and I'm releasing THE KRAKEN.
When you said you're not sure it's right - I agree. Further, I post what I believe to be true based on the ability to read and comprehend at the college level. Thus, what matters to me is the uplist to Nasdaq and getting the clinical trials underway. Management coming forward with a Code of Ethics (required by Nasdaq) is helpful for confidence moving forward, and the Q&A plus Dr. David Nutt and the Spirit Molecule Dr. Rick Strassman are on the DMT psychedelic team. Who knows more about psychedelics than those two individuals? That's enough for me to stop looking back and whining like a child after every news release or event on Algernon's calendar. A good question is are people hell bent on whining about what I post more than what they actually believe about the company? I've been posting here through the storm. This message board would have been dead not for my relentless posts. I have not changed. Things I've screamed about changing with the company have. Late yes, but there have been significant changes to the betterment of shareholders. We shall see how management performs with it's 2022 list of accomplishments. The ink isn't dry on any of it and people are already screaming about failures. That's just crazy talk, but it's the CSE/OTC. Expect nothing less until an uplist to Nasdaq where expert analysts will take over the narrative. At that point I may even stop posting here period and spend that time elsewhere. It's long overdue for a long.
M$
There's cures and there's treatments. What do rocks have to do with anything? It's a biotech stock. Algernon's chances at Phase 1 and Phase 2 are just as sound as any other biotech chasing cancer or whatever given Ifenprodil's known safety history. Those who hate the story and/or refuse to wise up on the facts will complain no matter the circumstances. I do my own due diligence to form an opinion. Others use others due diligence to form an opinion about someone else's opinion. Definitely a difference.
Furthermore, if biotech companies took the short view of defeatism with the odds of cancer treatments, society would be at a devastating loss beyond any pandemic in history. Thank goodness we have people of courage and conviction to treat and cure cancers in all it's forms, but as always CSE/OTC investors are smarter than everyone else who can read and comprehend well above the high school level.
Question: At what price did you dump your shares as you stated in a previous post - surely it was less than 6 $. Maybe the double up plan ain't working too well huh?
peace,
M$
Postscript
Two-thirds of all adults cannot read/comprehend what they read beyond the 5th grade level. Therefore, illiteracy runs wide and deep throughout society. CSE/OTC is a microcosm of that very sad fact. A move to Nasdaq ASAP is a must for Algernon Pharmaceuticals Inc.
Just a few things regarding the Annual Information Form
The Development of a Therapy for Pancreatic Cancer
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis
https://www.globenewswire.com/news-release/2022/01/28/2374942/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-Application-for-Idiopathic-Pulmonary-Fibrosis.html
80,615 views Streamed live 17 hours ago
Streetwise Live!
28.5K subscribers
Hear How Psychedelic Drugs Can Make Brain Cells Grow and Repair Themselves
Learn About DMT and How it Will Soon be Clinically Tested to Help Stroke Patients
Listen to Two World Renowned Psychedelic Drug Experts (Professor David Nutt and Rick Strassman MD) on Why DMT Might Work
It's On Now @ This Link:
Meanwhile...Streetwise Live! Presents Algernon Pharmaceuticals
Thursday, January 27th, 2022 at 2:30 PM ET
Featuring Christopher Moreau, Dr. Rick Strassman and Dr. David Nutt
Since 2001, Streetwise Reports has been the place where investors go to read about promising investment ideas straight from leading industry experts, analysts, newsletter writers and money managers.
Now we've decided to take it one step further! We are offering investors the rare opportunity to tune-in online via Streetwise Live! and learn from guests Christopher Moreau, CEO, Dr. RIck Strassman and Dr. David Nutt as they discuss upcoming catalysts and events.
There is NO COST to attend this event. Simply fill out the form below and we will send you the viewing information.
This type of intellectual capital is usually not made available to the general public, but Streetwise Reports is your "In."
https://www.streetwisereports.com/events/register/?event_id=100&utm_source=SWR_MC
Just great! A section of a wasted read (time) lifted from a group of wack-a-doodle COVID-19 conspiracy theorists and anti science wingnuts.
Hunting down your sources is not entertaining to say the least of it.
Given the full context of the article I would have been embarrassed to provide a link also.
Also, the article refers to off label drugs in the USA that have been previously FDA approved for use.
VERSUS
Off label drugs that have never been FDA approved for use in the USA or EU.
BIG DIFFERENCE
Know what you own if anything.
peace,
M$
Sarbanes-Oxley Act: Code of Ethics Requirement
Section 406 of the Sarbanes-Oxley Act outlines code of ethics requirements for senior financial officers. Taken directly from the act, a code of ethics comprises the standards necessary to promote "honest and ethical conduct; full, fair, accurate, timely and understandable disclosure in periodic reports;" and "compliance with applicable governmental rules and regulations." Any changes to an established code of ethics must promptly be disclosed to the public via the Internet or other electronic means.
NASDAQ BOUND!
Hallelujah.
Keep rolling out the good (due diligence) news Shell.
peace,
M$
Outro
FDA rejects Merck cough drug NDA, briefly weighing on Bellus
By Richard Staines
Jan. 24, 2022
Merck & Co Inc. has had a setback with its chronic cough drug gefapixant after the FDA rejected its NDA, a decision that also briefly hit the share price of rival Bellus Health Inc. before it regained market traction late Jan. 24. The FDA had been reviewing gefapixant since March 2021, but the regulator is now asking for additional information related to measurement of efficacy in a dreaded complete response letter. Merck said the response was not related to the safety of gefapixant, a P2X3 receptor antagonist, under development for treatment of refractory chronic cough (RCC) or unexplained chronic cough in adults. Shares in Merck (NYSE:MRK) ticked down 1.4% to $78.86 while Bellus Health shares (NASDAQ:BLU) rose by 1.8% to $5.66.
Roy Baynes, senior vice president and head of global clinical development, said Kenilworth, N.J.-based Merck remains “committed” to continuing development of gefapixant. The company is reviewing the letter and will meet with the FDA to discuss next steps.
Stuart Green, vice president and therapeutic area head for late-stage clinical development for respiratory and immunology at Merck Research Laboratories, told BioWorld, “At this time, we do not believe additional clinical trials will be necessary to satisfy the questions raised in the CRL.”
Green said it would be “premature” to provide timings for a potential new review with the FDA.
Analyst Josh Schimmer of Evercore said there were two potential explanations for the CRL based on the minimal information released by Merck.
Phase III data showed a reduction in cough frequency of around 20% – a treatment effect that may not have been strong enough as the FDA has no clear threshold for cough reduction. Data may have not held up after sensitivity or unblinding analyses, he added.
The FDA may require more dose-finding work as a 15mg dose wasn’t effective and there were also high rates of taste disturbance – around 60% – with 15% of patients discontinuing treatment.
Bellus readthrough?
Bellus of Laval, Quebec is also having trouble developing a P2X3 receptor antagonist in chronic cough – its potential rival BLU-5937 failed in a phase II trial in July 2020.
Despite that, the company managed to stay in the game with positive phase IIb trial results in RCC announced late last year and has since raised $200 million with its dual Toronto Stock Exchange/Nasdaq listing to fund further development.
Schimmer said there were positives and negatives for Bellus from today’s announcement. Bellus may learn from any additional data produced by Merck, which could struggle to market gefapixant because of its “modest profile”.
However, weighing against Bellus is the lack of clear threshold for chronic cough drugs and a lack of urgency to approve them. BLU-5937’s profile could also be diminished by pending phase III trial data and Bellus may have more work to do on dosing, Schimmer said.
Nerre opted for rare disease focus
Merck’s troubles follow Nerre Thrapeutics Ltd. July announcement that it was taking another shot at showing its chronic cough treatment was effective in July last year.
A £20 million ($27.6 million) funding round allowed the Stevenage, U.K.-based biotech to run a second phase II trials of its neurokonin1 antagonist orvepitant.
The second trial had a different patient-focused primary outcome of chronic cough caused by idiopathic pulmonary fibrosis.
Nerre chose a rare disease indication for orvepitant after it failed to meet the endpoint of reducing awake cough frequency in an all-comers phase IIb trial of 315 patients with refractory chronic cough.
Last week, Japan’s Ministry of Health, Labour and Welfare approved gefapixant under the brand name Lyfnua for adults with refractory or unexplained chronic cough.
https://www.bioworld.com/articles/515387-fda-rejects-merck-cough-drug-nda-briefly-weighing-on-bellus
Q&A Video Presentation: Algernon Pharmaceuticals (AGN) - Presentation, Deep Dive and Q&A with CEO Christopher Moreau
https://www.youtube.com/watch?v=o1RmM0P-8uM&t=5s
Fund Triples Holding of Drug Repurposing Firm
Streetwise Reports (1/20/22)
The Quick Take
AlphaNorth Partners Fund more than tripled its position in Algernon Pharmaceuticals in December.
The fund bolstered its Algernon holding at the average purchase price of $4.61 per share, which indicated a "very compelling" $7.8 million valuation, AlphaNorth noted.
AlphaNorth noted that 2022 should be a catalyst-rich year for
Algernon, with the:
Launch of a clinical trial evaluating the psychedelic compound DMT as a treatment for patients after a stroke.
Q2/22 data readout from Algernon's Phase 2 trial of Ifenprodil in idiopathic pulmonary fibrosis/chronic cough.
Advancement of additional drug candidates into the clinic this year.
Algernon is well cashed-up with more than $2 million on the balance sheet.
The 2021 return of AlphaNorth Partners Fund was about 22%, above the 7.3% return of the TSX Venture Exchange index.
http://www.thelifesciencesreport.com/article/2022/01/20/fund-triples-holding-of-drug-repurposing-firm.html
Streetwise Live! Presents Algernon Pharmaceuticals
Thursday, January 27th, 2022 at 2:30 PM ET
Featuring Christopher Moreau, Dr. Rick Strassman and Dr. David Nutt
Since 2001, Streetwise Reports has been the place where investors go to read about promising investment ideas straight from leading industry experts, analysts, newsletter writers and money managers.
Now we've decided to take it one step further! We are offering investors the rare opportunity to tune-in online via Streetwise Live! and learn from guests Christopher Moreau, CEO, Dr. RIck Strassman and Dr. David Nutt as they discuss upcoming catalysts and events.
There is NO COST to attend this event. Simply fill out the form below and we will send you the viewing information.
This type of intellectual capital is usually not made available to the general public, but Streetwise Reports is your "In."
https://www.streetwisereports.com/events/register/?event_id=100&utm_source=SWR_MC
Nice Find. Thx tcm55.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167588412
M$
It's the Penny World Three Stooges Effect.
No Rhyme. No Reason.
Just Stupidity @ Work.
peace,
M$
I agree with the CEO's original thought before he walked it back. That being, most of the CSE/OTC shareholders are complete morons. Hence, The 3 Stooges Act I'm responding to today. The move to Nasdaq ASAP will do the stock wonders in the sense that more people with common sense will have eyes, ears, and hopefully their money on the stock. The narrative of Algernon left in the hands of people who can't see the consolidation provides a better opportunity moving forward remains stuck in penny world thoughts, and most likely have never dealt with a stock positioning itself to trade in the triple digits with a low float, low volume, less volatility and chaos. They are out of their comfort zone and sheer fear has taken over. The days of these same people cheering on ten cent increases here and there is where they'd rather be - Green Acres. My best guess is no matter what many of the same people will find any reason to complain here. I've been the biggest critic of the company. No one else comes halfway close to the public scrutiny I’ve laid at the foot of management. I put my marker down long ago and devoted time to educating the masses about the ins and outs of management’s moves. Do you honestly think/believe I have not influenced the company for the better? WTF Ever. So here I am, finally in a mode to move forward with the company messaging and out of the shadows comes the same cast of characters wanting to hold the story back. News Flash: You cannot and will not change the trajectory of the company moving forward. Once Algernon's story is in the hands of Nasdaq stock analysts, sophisticated investors, institutional investors, and media outlets the company will not have to pay (free ink), many of the baseless angles by stooges will seem even more ridiculous if possible. Having interacted with today's messages I've surely spent my time entertaining the cheap seats in the arena. Out of all, the one thing today that's most disappointing is folks who have followed this message board for years have a slower overall perspective of the company's direction than two brand new bloggers who recently stumbled along and summed up Algernon's story in no time flat. That's the type of learning curve Algernon seeks from investors with a Nasdaq listing.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167529403
http://www.321gold.com/editorials/moriarty/moriarty011822.html
We Seek Safe Harbor,
M$
Outro
Sir, I am following absolutely nothing you are talking about. We are in two completely different worlds here. Good luck with your baseless theories.
M$
You appear to be really hung up on the pr's. You mention it in nearly every post now. You must have a news editor background. Maybe discuss a roll at HQ with your beer buddy? Seems as if not many here are ready to turn the page.
peace 3x,
M$
Just in case another straggler comes along with a baseless (without foundation in fact) thought about Algernon's DMT treatment plan, please refer them to this link:
Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study
www.globenewswire.com/news-release/2021/11/01/2324220/0/en/Algernon-Pharmaceuticals-Establishes-6-hours-as-Optimum-Treatment-Period-for-DMT-in-Neuron-Study.html#:~:text=The%20data%20showed%20that%20an,treatment%20time%20periods%20and%20doses.
eqinvestor
I'm not about to provide you with a crash course here. Simply do much more due diligence. You are completely off base with most of what you posted. The only point I will make is your opinion appears to be very myopic/anal. Let's just forget about Small Cell Lung Cancer - Pancreatic Cancer - IPF/Chronic Cough data readout (Q2) - Two New Drugs Acquired and one from the Far East not yet fully disclosed (hmm) - Nasdaq listing. All in 2022. Also, that Q&A session was a good start of a turning point to show competency and credibility.
peace,
M$
1/19/21 Video: The Market Herald
Health Care, Psychedelics, Sponsored, The Power Play
Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study
https://themarketherald.ca/algernon-pharmaceuticals-files-for-clinical-trial-and-ethics-approval-for-phase-1-dmt-human-stroke-study-2022-01-19/
1/19/21 Algernon Pharmaceuticals files for Clinical Trial and Ethics Approval for Phase 1 DMT human stroke study
https://www.proactiveinvestors.com/companies/news/971588/algernon-pharmaceuticals-files-for-clinical-trial-and-ethics-approval-for-phase-1-dmt-human-stroke-study-971588.html
What I know is the CEO was not ready to unload that type of information. What we do know is the Phase 1's are somewhere between 1 and 2 Million CAD. The Phase 2 is 4 to 5 Million CAD. That's what I recall the CEO saying. I could be wrong. Waiting for the Q&A to post @ YouTube. I believe the CEO said something to the effect of you do the math with 2M+ CAD on hand. Timing of raising capital likely revolves around the uplist to NASDAQ (We hope no L8R than early March). During the Q&A I posed the question at what targeted share price management plans to list on NASDAQ come day one. The question was never asked. Hence, never answered. What I believe is the valuation numbers for an uplisting is still being hammered out. Those two bloggers that popped up out of nowhere maybe part of the picture in terms of trying to educate the market to the hidden value being suppressed on the CSE/OTC. It remains my belief Algernon should uplist for no less than $30 per share USD. From there raise capital without attached warrants. Target institution investors who've got a clue about the pipelines explosive potential. For someone whose got both feet out the door here, you still got your head stuck in the room.
In My World: 10 Million USD @ 30 USD per share Get's Algernon through calendar year 2022, and the next capital raise would be triple digits per share. None of the raises to include warrants (toxic financing). The CEO can't keep saying on one hand how exciting and dynamic the pipeline is, but on the other hand keep giving the store away. Let's get at some of that institutional investor money sitting out there on the sidelines.
Please forward all your financial inquires here:
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
GL2U
M$
P.S. If you tuned into the Q&A the other day you were told all financial questions were off the table.
Furthermore, I posted what initially stood out to me directly after the Q&A.
investorshub.advfn.com/boards/read_msg.aspx?message_id=167533051
Holding hands should not be part of your investment strategy.
DYODD
Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study
VANCOUVER, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational Medicinal Products and Ethics Approval application, with the United Kingdom Medicines and Healthcare Products Regulatory Agency (“UK MHRA”). This was accomplished via the combined review service, which provides for a single application route for its planned Phase 1 clinical human study of AP-188 (“N,N-dimethyltryptamine” or “DMT”). DMT is a known psychedelic compound that is part of the tryptamine family.
The Company announced on November 19, 2021, that it had received positive feedback at a scientific advice meeting from the UK MHRA for its planned Phase 1 DMT Stroke study.
The primary focus of the Phase 1 DMT study is to investigate prolonged intravenous infusion of DMT, for durations which have never been clinically studied. The resulting data generated will help the Company to plan both its Phase 2 acute stroke and rehabilitation studies more effectively.
“We look forward to getting our DMT clinical stroke program started with our Phase 1 study at Hammersmith Medicines Research in the UK,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals. “This study will provide important information on dosage and duration of our new DMT IV formula to help us better plan for our Phase 2 study where we plan to test the drug with both acute and recovering stroke patients.”
Phase 1 DMT Stroke Study Summary
The purpose of the study is to identify the safety, tolerability, and pharmacokinetics of DMT when administered as an intravenous bolus followed by prolonged infusion. The first part of the study will use a single-escalating dose design aimed at identifying the maximum sub-psychedelic dose, while the second part will test the effects of repeated administrations of this dose. There will be up to 96 healthy volunteers enrolled across the two parts of the study which will include both psychedelic experienced and psychedelic naïve patients.
About DMT
N,N-Dimethyltryptamine, or DMT, is a hallucinogenic tryptamine drug producing effects similar to those of other psychedelics like LSD, ketamine, psilocybin and psilocin. DMT occurs naturally in many plant species and animals including humans and has been used in religious ceremonies as a traditional spiritual medicine by indigenous people in the Amazonian basin. DMT can also be synthesised in a laboratory.
Algernon has filed provisional patents for new forms of DMT, in addition to formulation, dosage and method of use claims for ischemic stroke. The Company has also filed claims for combination therapy of DMT and stroke rehabilitation including Constraint Induced Movement Therapy.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
Please put your money where your mouth is.
I have.
peace 2x,
M$
With your recommendation on the table for all, I recommend you sell and sell now. Which recommendation do you think is better, yours or mine? I find it truly amazing how some investors can't put two and two together when it comes to understanding the market cap. For the last time. The friggin float is ultra low. The stock price has room to grow by 1000's of percentages from here. You have two bloggers in two days who have done their due diligence come forward and basically say the exact same thing. I've been saying it for quite some time now. You know I'm long the stock. Yet, I'm asked about selling before any true fireworks jump off. If you believe Algernon is a 10M or less market cap company then by all means get out and get out now before the bottom falls out. Otherwise, wise up and let the story unfold. Good news remains bad news in some shareholders eyes. They will never be satisfied. I get it!!! I get the story has been pure hell up to this point. I have fought like hell for a better story coming from the company. IMO, we are finally there with a real path to success throughout the pipeline.
peace,
M$
My understanding is we shouldn't expect the uplist until the end of February/beginning of March (3 month timeline from date of application).
Which means both Phase 1 cancer studies could potentially be underway before the uplist to NASDAQ.
The SCLC and Pancreatic Cancer studies are targeted for non-dilutive financing (perhaps Grants at minimum of 50% of the cost if not 100%).
The DMT Phase 1 and DMT Phase 2 are the two studies up for a capital raise in 2022. As Chronic Cough will likely not advance in 2022 because of the timing of the IPF/CC data readout in Q2 2022.
My best guesstimate for a capital raise in 2022 is upwards of 10 Million USD.
The big question remains as to when will they pull the trigger and at what price for shares - and if warrants will be attached?
The questions regarding financing, like toxic financing (shares+ warrants) was off the table in the Q&A per the CEO.
peace 4x,
M$
Yes Sir. Thank you. Overall, the CEO made a very good impression for the company moving forward - wearing a tie "suits" him well. However, the devil still remains in the timelines staying on track and dilution of course. That very last question posed by someone about insider ownership of less than 2% was an OUCH for the CEO. A question he surely would rather have not been positioned to answer. Thus, the on the spot non scripted Q&A's is the way to go. The CEO should hold them more often. It strengthens his leadership capabilities.
peace 3x
M$
Re: Webinar
CEO did not seek a preliminary listing eligibility review by Nasdaq's Listing Qualifications Department prior to applying.
CEO says he believes the company/team has all the competency necessary to be eligible for NASDAQ Capital Market listing requirements.
CEO said timeline for NASDAQ uplist is a few months.
CEO says he was misquoted in an article about the dumber than a box of rocks Canadian investors of Biotech stocks.
CEO says it's just more sophisticated investors in numbers at NASDAQ versus CSE/OTC - he wasn't trying to offend anyone.
CEO will not discuss financing as it relates to capital raises.
CEO tells everyone to do their own due diligence and piece the math together based on currently available information.
CEO has not committed to a stand-alone Chronic Cough study in the USA in 2022.
Entire webinar will be posted to YouTube once edited for continuity.
The above are just some of the things that stood out to me while en-route to my next out of town destination.
peace,
M$
PostScript
CEO talked about his friend telling him his shares were decimated by the 1 for 100 reverse split. Friend had 100,000 shares and now he only has 1000 shares. The CEO told his friend and everyone else to "Do The Math". You still have the same amount of money in your account - example being having five 20 Dollar bills in your pocket or One Hundred Dollar bill in your pocket.
IMO, the CEO's basic analogy still does not take into account the psychological effect on shareholders in the stock and would be shareholders buying the stock. It's easier to sell a One Dollar stock/story than it is to sell a One Hundred Dollar stock/story. It's the psychological toll that has taken place with a severe 1 for 100 reverse split. It also makes as if there's a lot of room to dilute the company like crazy as if the previous credit score no longer exists. Meaning, management starts spending/diluting as if we are all brand new here. Hopefully, the CEO's beer buddy will come to mind when it comes time to raise capital. Capital the CEO chose not to discuss in the webinar.
P.S.S Thank you HealthMngr. I had my information mixed up regarding the actual day of the webinar. I was thinking the webinar was tomorrow given the US markets were closed today. I thought for sure I pulled up market hours for the CSE and it stated the market was closed. Had Shell not posted that stock information earlier I would have thought the CSE was not trading. In any event I had time to chime in of course. My time will be tied up tomorrow on the golf course. peace 2x
Quik Correction: I was calculating value assuming Bay Bridge Bio was using CAD valuations. Bay Bridge Bio is a Berkeley, CA blog. So, the overall USD valuation of Algernon with two Phase 1's and one Phase 2 in the workings is $424 Million USD @ $250 per share.
The above numbers assumes no further dilution of the current 1.7 million outstanding shares.
About Bay Bridge Bio:
https://www.baybridgebio.com/about.html
M$
Quick follow up: The business model of Algernon is now geared towards institutional investors (big money). Looking at the valuation numbers used by PQ and Bay Bridge Bio, it's way more likely folks in Pennyland would be willing to shovel out a dollar or two per share at Phase 1 and Phase 2 versus $100 or $200 at Phase 1 and Phase 2. It's not only the mindset but the overall pool of people with the money to put on the line. Listing at NASDAQ ASAP is our #1 concern to date.
peace,
M$
The "PennyQueen" is using a stock valuation of 180M CAD (143M USD) based on Bay Bridge Bio's valuation model.
https://www.baybridgebio.com/drug_valuation.html#!
Here's what PennyQueen calculated to date:
PQ
Question #1: Did you seek a preliminary listing eligibility review by Nasdaq's Listing Qualifications Department prior to applying?
Question #2: If not, why not?
Here is the following language from Nasdaq regarding a preliminary listing eligibility review:
listingcenter.nasdaq.com/Material_Search.aspx?cid=34&mcd=LQ